PT - JOURNAL ARTICLE AU - Sun, Kaiyuan AU - Wang, Wei AU - Gao, Lidong AU - Wang, Yan AU - Luo, Kaiwei AU - Ren, Lingshuang AU - Zhan, Zhifei AU - Chen, Xinghui AU - Zhao, Shanlu AU - Huang, Yiwei AU - Sun, Qianlai AU - Liu, Ziyan AU - Litvinova, Maria AU - Vespignani, Alessandro AU - Ajelli, Marco AU - Viboud, Cécile AU - Yu, Hongjie TI - Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2 AID - 10.1101/2020.08.09.20171132 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.09.20171132 4099 - http://medrxiv.org/content/early/2020/08/13/2020.08.09.20171132.short 4100 - http://medrxiv.org/content/early/2020/08/13/2020.08.09.20171132.full AB - A long-standing question in infectious disease dynamics is the role of transmission heterogeneities, particularly those driven by demography, behavior and interventions. Here we characterize transmission risk between 1,178 SARS-CoV-2 infected individuals and their 15,648 close contacts based on detailed contact tracing data from Hunan, China. We find that 80% of secondary transmissions can be traced back to 14% of SARS-CoV-2 infections, indicating substantial transmission heterogeneities. Regression analysis suggests a marked gradient of transmission risk scales positively with the duration of exposure and the closeness of social interactions, after adjusted for demographic and clinical factors. Population-level physical distancing measures confine transmission to families and households; while case isolation and contact quarantine reduce transmission in all settings. Adjusted for interventions, the reconstructed infectiousness profile of a typical SARS-CoV-2 infection peaks just before symptom presentation, with ~50% of transmission occurring in the pre-symptomatic phase. Modelling results indicate that achieving SARS-CoV-2 control would require the synergistic efforts of case isolation, contact quarantine, and population-level physical distancing measures, owing to the particular transmission kinetics of this virus.Competing Interest StatementHongjie Yu has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. All other authors declare no competing interests.Funding StatementHongjie Yu acknowledges financial support from the National Science Fund for Distinguished Young Scholars (number 81525023) and the National Science and Technology Major Project of China (numbers 2018ZX10201001-010, 2018ZX10713001-007, and 2017ZX10103009-005). Lidong Gao acknowledges financial support from Hunan Provincial Innovative Construction Special Fund: Emergency response to COVID-19 outbreak (No. 2020SK3012). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional review board from Hunan Provincial Center for Disease Control and Prevention (IRB#2020005). Data were deidentified, and informed consent was waived. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe datasets generated during and/or analyzed during the current study are not publicly available due to privacy concerns but are available from the corresponding authors on reasonable request.